Actively Recruiting
Psilocybin Therapy for Depression in Parkinson's Disease
Led by Joshua Woolley, MD, PhD · Updated on 2025-05-13
60
Participants Needed
1
Research Sites
197 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
CONDITIONS
Official Title
Psilocybin Therapy for Depression in Parkinson's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 40 to 80
- Comfortable speaking and writing in English
- Diagnosed with idiopathic Parkinson's disease by a neurologist, Hoehn and Yahr stages 1 to 3 during an "on" phase
- Currently experiencing depressive symptoms
- Able to attend all in-person visits at UCSF and virtual visits
- Have a primary care provider, neurologist, or psychiatrist actively managing or coordinating care
You will not qualify if you...
- Psychotic symptoms involving loss of insight
- Significant cognitive impairment
- Regular use of medications that may interact problematically with psilocybin
- Any health condition making the study unsafe or unfeasible as determined by study physicians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
B
Brigette Sosa
CONTACT
E
Ellen Bradley, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here